Market capitalization | $1.21b |
Enterprise Value | $1.27b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 7.15 |
EV/Sales (TTM) EV/Sales | 1.15 |
P/S ratio (TTM) P/S ratio | 1.09 |
P/B ratio (TTM) P/B ratio | 1.02 |
Sales growth (TTM) Sales growth | -13.02% |
Turnover (TTM) Turnover | $1.10b |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
9 Analysts have issued a Omnicell, Inc. forecast:
9 Analysts have issued a Omnicell, Inc. forecast:
Mar '24 |
+/-
%
|
||
Turnover | 1,103 1,103 |
13%
13%
|
|
Gross income | 470 470 |
18%
18%
|
|
EBITDA | 146 146 |
45%
45%
|
EBIT (operating result) EBIT | -20 -20 |
1,101%
1,101%
|
Net profit | -21 -21 |
20%
20%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.
Head office | United States |
CEO | Randall Lipps |
Employees | 3,650 |
Founded | 1992 |
Website | www.omnicell.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.